Category: CannabisNewsWire Release

420 with CNW — Ukraine War, Supply Chain Issues Increase Marijuana Production Costs

Ever since the supply chain problems triggered by the pandemic were worsened by Russia’s invasion of Ukraine, cannabis producers are facing rising costs that could shake the industry in ways that have never been seen.

Russia and Ukraine together account for 28% of NPK fertilizers (nitrogen, phosphorous as well as potassium) sold on the world market. The war and the sanctions placed on Russia have shaken this supply source, and the cannabis industry as well as other segments of the agricultural industry is feeling the heat.

“Modern Farmer,” a magazine published every quarter, paints a graphic picture of how fertilizer prices have gone up in recent times. It writes that the price of anhydrous ammonia has risen by 225%, while the price of liquid nitrogen has gone up by 192%. Urea has seen a 149% price hike over the past 12 months.

The news agency Reuters also estimates that after registering a 17% price increase last year, fertilizer prices are likely to increase by at least 12% this year.

These price increases are so serious that the U.S. federal government announced in June that it plans to double its initial investment of $250 million so that efforts to produce fertilizers locally are boosted. However, the cannabis industry isn’t too excited about this development because the feds are likely to be more interested in supporting farmers of crops such as soy or corn rather than spreading the benefits of this push across the board.

These price increases as well as the supply chain hiccups that started when the pandemic struck suggest that players in the cannabis industry need to be innovative and find ways to weather this storm. For example, there is need to rethink how procurement is done so that companies can buy in bulk instead of buying small batches of inputs at the precise moment when those inputs are needed. This consolidation will ensure that the cultivators get what they need and at reasonable prices instead of buying at a higher price each time they reenter the market.

Producers can also become more conscious about fertilizer use in order to use just enough to give the expected yield without anything going to waste. For example, many fertilizer manufacturers recommend product usage that is at the higher end of the spectrum, but cannabis plants can grow well with much less fertilizer application.

Technologies such as electrical activity monitors can also alert farmers when their fertilizer use has reached the optimum level, hence preventing waste during cultivation. Regenerative farming methods can enable cultivators to depend on fewer artificial inputs, thereby cushioning themselves from the inflation affecting conventional growers.

While the shocks the industry is facing are the same, they aren’t affecting all industry players, including American Cannabis Partners, in the same way since these external factors normally find a differing mix of internal efficiencies or weaknesses.

NOTE TO INVESTORS: The latest news and updates relating to American Cannabis Partners are available in the company’s newsroom at https://cnw.fm/ACP

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Advanced Container Technologies Inc.’s (ACTX) Innovative Growing Systems Offering Numerous Advantages

Advanced Container Technologies (OTC: ACTX), the exclusive U.S. distributor of GrowPods, is seeing interest in the environmentally controlled micro-farms that allow cultivation of ultraclean crops year-round. According to a recent article that contains excerpts from a GreenBiz piece titled, “How Vertical and Indoor Farming Can Supplement the Food Supply Chain,” innovators have developed new technologies such as indoor and vertical farms designed to supplement outdoor farming and solve the issue of limited cultivation land. The piece notes that “the systems often recirculate water, which can be more efficient than how water is used for other types of crops. Light and temperature can also be controlled, and since there is no exposure to pests, no chemistry is needed…. [The farms] can be built anywhere. That means food such as leafy greens can be grown closer to population centers.” Experts also believe that while indoor and vertical farming will not feed the world, it can supplement the supply chain. “These are only a few of the advantages that GrowPods, which are self-contained, automated, indoor micro-farms, offer users. These innovative containerized growing systems are designed with functionality and ease of use in mind. The pods are configured to optimize plant growth while minimizing labor; setup is quick and simple, no pesticides are needed, and the containers produce harvests all year long.”

To view the full article, visit https://cnw.fm/vrVue

About Advanced Container Technologies Inc.

Advanced Container Technologies is in the business of selling and distributing self-contained, automated, indoor “micro-farms” called Grow Pods, along with related equipment and supplies. Additionally, the company designs and sells patented proprietary medical-grade plastic containers, known as the Medtainer(R), that store and grind pharmaceuticals, herbs, teas and other solids or liquids. For more information, visit the company’s website at www.AdvancedContainerTechnologies.com.

NOTE TO INVESTORS: The latest news and updates relating to ACTX are available in the company’s newsroom at https://cnw.fm/ACTX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Awards Exclusive License to Japan’s Premier Wellness Science Co.

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has awarded licensing of its proprietary DehydraTECH(TM) offering for development in Japan to Premier Wellness Science Co. Ltd, a wholly owned subsidiary of Premier Anti-Aging Co. Ltd. LEXX announced that Premier is purchasing exclusive rights to DehydraTECH technology for the Japanese nonpharmaceutical market; the company will use the tech in oral liquid and nonliquid products, as well as for topical, hair-care, lip-care and cosmetics products. According to the announcement, Lexaria will receive minimum payments of $4,527,500 over the next five years, as all well as royalties from the sales of products made with DehydraTECH, which the company anticipates could be significantly greater than the minimum payments. In addition, the two companies agreed to explore the possibility of R&D collaborations. An official from Premier noted that the company partnered with Lexaria based on DehydraTECH’s superior performance and the extensive data available through Lexaria’s years of testing. “Lexaria is delighted to be working with Premier Wellness Science, which we expect will dominate the newly opening Japanese market for CBD-based products,” said Lexaria CEO Chris Bunka in the press release. “Premier and Lexaria share similar philosophies, such as the provision of world-leading products created through scientific advantages and placing the consumer’s needs ahead of our own. We could not have found a better partner with which to introduce DehydraTECH-enabled products to the Japanese markets.”

For more information, view the full press release

About Lexaria Bioscience Corp.

Lexaria Bioscience’s patented drug-delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 25 patents granted and more than 50 patents pending worldwide. For more information about the company, please visit www.LexariaBioscience.com. 

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Mines Potential of Helping Medicines Do What they Do, But Better

  • Lexaria Bioscience is a global innovator in drug delivery platforms, developing a technology designed to improve the performance of other medicinal products by making them more rapidly and effectively usable by patients’ bodies
  • Lexaria’s patented DehydraTECH technology has been studied in combination with a number of other products, including but not limited to, cannabidiol (“CBD”), oral nicotine, antivirals, NSAIDs, and erectile dysfunction therapies
  • The company is pursuing FDA approval under the Investigational New Drug (“IND”) process to clinically test its DehydraTECH-CBD for the treatment of high blood pressure
  • A driving focus of the company’s R&D has been to improve the speed of onset, increase bioavailability and brain absorption of active pharmaceutical ingredients

A common refrain in the world of advertising medicinal substances is that a select product can enhance a patient’s ability to live an active life despite debilitating medical conditions. 

“By helping to control eczema with Dupixent you can show more (skin),” one prominent ad message declared in recent months, while another offered examples of hope by testifying, “Opdivo plus Yervoy equals a chance for more starry nights” (https://cnw.fm/yBxCG). 

Drug delivery innovator Lexaria Bioscience (NASDAQ: LEXX) has found a market niche in the potential of enhancing medicines’ ability to do what they do. The company’s patented DehydraTECH(TM) technology has been tested in combination with a variety of active pharmaceutical ingredients (“APIs”), processing the drug substances through a proprietary dehydration process for rapid-absorption delivery. 

“Lexaria has repeatedly demonstrated that DehydraTECH-processed cannabidiol (‘CBD’) has superior delivery characteristics into the bloodstream and brain compared to generic CBD and expects to generate similar results with THC,” the company stated in regard to one set of substances last year (https://cnw.fm/jiX9J).

Lexaria is pursuing U.S. Food and Drug Administration (“FDA”) approval to begin formal, registered clinical testing for using DehydraTECH-CBD to treat hypertension following a series of successful studies.

“Lexaria has repeatedly demonstrated that DehydraTECH-processed nicotine has superior delivery characteristics compared to generic nicotine when dosed orally and swallowed for intestinal delivery to the bloodstream,” the company added in regard to another progressing area of R&D.

“Phosphodiesterase-5 inhibitor (PDE5) drugs work using a process of vasodilation, and most are considered to be slow-acting, requiring 1-2 hours to reach peak levels in the bloodstream for maximum effectiveness,” Lexaria stated in regard to still other products treating erectile dysfunction (“ED”). “Lexaria has repeatedly evidenced a greatly reduced delivery time of another drug that encourages vasodilation – DehydraTECH CBD – and theorizes whether DehydraTECH might likewise deliver PDE5 drugs more quickly and effectively. … DehydraTECH for PDE5 drugs is patent pending.”

 The Company recently announced its 25th patent has been awarded for for the use of DehydraTECH technology in the enhanced delivery of antiviral drugs — its first patent to build on studies processing antivirals such as remdesivir and ebastine with DehydraTECH to fight the COVID-19/SARS-CoV-2 virus and other biosystem invaders (https://cnw.fm/Re39u).

Lexaria will commence its human oral nicotine study NIC-H22-1 this summer.  The Company is optimistic that this larger human study will produce positive findings pursuant to those evidenced in its previous 2021 subjective human testing that utilized DehydraTECH-nicotine formulations demonstrating onset of initial nicotine effectiveness in as little as 1.5 to 4 minutes after an oral dose. As the body of data regarding DehydraTECH has grown, its use in improving outcomes for a variety of conditions has generated widespread corporate optimism.

“If we can sustain these results, we could be looking at mega-drug status ($1 billion per year) in the hypertension market,” CEO Chris Bunka stated last year in regard to the DehydraTECH-CBD studies (https://cnw.fm/WRGRV). “Our goal now is to put together a 4-week study, three doses per day, targeting a sustained drop in blood pressure. That could make us one of the most effective registered pharmaceutical treatments for hypertension in the world, with few if any unwanted side effects.”

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — DOJ Report Says Federal Cannabis Arrests Continue to Decline Annually

According to new data released by the U.S. Department of Justice, federal arrests connected to marijuana have continued to plummet each year as states continue reforming their cannabis laws and creating markets for this substance. The report says that the number of people arrested by the U.S. Drug Enforcement Administration has registered an annual 11% decline from 2010. In that year, a total of 8,215 arrests connected to marijuana charges were made by the federal agency. However, the figure has dropped over time to the 2,576 arrests on record in 2020.

It isn’t immediately clear which specific factors are behind the drop in arrests, but the DEA says the COVID-19 pandemic, which was at its peak in 2020, was responsible for a huge decline (81%) in the number of people arrested on marijuana charges between March and April 2020, when stay-at-home orders had just been issued across the country. During those two months, cannabis prosecutions also registered a 77% slump.

However, marijuana industry advocates see the reason for the drop in a different way. They think that the Department of Justice has used its discretionary powers to refrain from pursuing low-level marijuana infractions, especially since the guidance provided during President Barack Obama’s time in the Oval Office urged the department to be less vigilant in going after marijuana users in states where such possession or use is permitted. The wave of cannabis legalization has also had a hand in reducing the frequency of arrests by the DEA, advocates say.

Of all the arrests connected to drugs, only 16% of those arrests were connected to marijuana. The vast majority of the arrests were related to methamphetamine, heroin and cocaine in powder form. The report clearly shows that of all drugs, cannabis has registered the steepest slump in the number of arrests conducted by the DEA.

It is also noteworthy that the DEA report says that most people serving time in federal prisons have a drug charge as the most serious offense they face. In fact, nearly half (47%) of the entire prison population have a drug charge to their name. In 2010, the fraction stood at 53%, so there is a decline in that regard as well.

Data from different sources backs up the findings of the DOJ. For example, the FBI authored a report in 2020 showing a nationwide drop in cannabis-related arrests. Also, 2018 research conducted by the Cato Institute concluded that the legalization of marijuana in different states had significantly reduced the rate at which marijuana was being smuggled into the country.

These statistics may indirectly suggest that the marijuana consumers have come to trust the products commercialized by licensed marijuana companies such as Flora Growth Corp. (NASDAQ: FLGC) in the jurisdictions where such companies are allowed to operate.

NOTE TO INVESTORS: The latest news and updates relating to Flora Growth Corp. (NASDAQ: FLGC) are available in the company’s newsroom at https://cnw.fm/FLGC

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Georgia Voters Endorse Ballot Question on Cannabis Legalization

Earlier last week, voters in the state of Georgia approved the language of a ballot measure expressing support for the legalization of adult-use marijuana. Democratic Party leadership in the state placed a number of nonbinding advisory questions on the primary election ballot to help inform lawmakers on where residents in the state stood on various issues, including cannabis legalization.

The question on legalization asked residents whether cannabis needed to be legalized, regulated and taxed in the same manner as alcohol for individuals aged 21 and above, with proceeds from its sale being directed toward health care, infrastructure and education programs. The cannabis initiative led by a strong margin of 80% with more than 99% of the counties having reported full results. While the vote’s results don’t change the state’s law, the high numbers of those in favor of legalization highlight the support for reform.

The state has open primaries, which means that any voter in Georgia could fill out the Democratic ballot on the day of election, regardless of what party they belonged to.

In addition to the question on marijuana legalization, questions on renewable energy, health care, free preschool, paid parental leave and the forgiveness of student loans were asked on the Democratic ballot. Meanwhile, the Republican ballot afforded individuals in the state a chance to comment on social media censorship, the right of transgender individuals to participate in sports and the Mexican border wall.

It should be noted that during this session, reforms to the state’s limited medical marijuana program advanced in both chambers but failed to be approved at the final passage.

In the past, Senate Democrats in the state of Georgia also tried enacting a measure that included provisions to decriminalize low-level possession of marijuana in 2020. However, the measure didn’t advance. This came after Democratic primary voters in the state of South Carolina were asked about their stance on the legalization of medical marijuana at the ballot in 2018. More than 80% of the voters’ response was in support of enacting a change in policy that would allow patients access to cannabis.

Last year, legislators in the Minnesota House also conducted a survey of residents as part of the State Fair Poll. Among the questions asked on the poll was how many were in favor of the legalization of adult-use marijuana. Results indicated that 58% of those who responded were in favor of reform. This figure was a slight increase in comparison to the 2019 survey that asked the same question, which found that 56% of the respondents would back the reform.

As many more states work to ease their cannabis prohibition policies, established cannabis companies such as Cannabis Strategic Ventures Inc. (OTC: NUGS) could end up spreading their footprint across state lines, especially when federal cannabis legalization takes place.

NOTE TO INVESTORS: The latest news and updates relating to Cannabis Strategic Ventures Inc. (OTC: NUGS) are available in the company’s newsroom at http://cnw.fm/NUGS

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) DehydraTECH Footprint Extends to Europe with License Granted to Valcon Medical

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has awarded licensing of its proprietary DehydraTECH(TM) offering for development in the European and United Kingdom markets. The company awarded the nonexclusive licenses to Valcon Medical A/S, a European contract manufacturing organization that specializes in the manufacturing of medical cannabis extracts for the EU and UK. According to the announcement, Lexaria will receive milestone fees and royalty payments from sales of products manufactured by Valcon.Valcon products will include an array of options, from nonregistered medical products through magistral programs to country-level market-authorized medical cannabis products through pilot programs; they will also include bulk powders or solid oral-dosage forms as well as powder-filled capsules, compressed tablets, pills, oral melts, and topical creams and lotions. “We are very excited to have licensed Lexaria’s DehydraTECH technology for what we expect will be rapid growth across the European markets,” said Valcon Medical A/S CEO Pete Patterson in the press release. “As Valcon continues to build out its manufacturing capabilities, we are developing new IP and partnering with industry leaders. Lexaria has developed and patented an incredible technology, which will benefit medical cannabis patients with enhanced bioavailability with a quicker effect onset. Backed by substantial clinical efficacy studies, Valcon will bridge the extensive work that Lexaria has done in the U.S., over to Europe.”

To view the full press release, visit https://cnw.fm/ffrpT

About Lexaria Bioscience Corp.

Lexaria Bioscience’s patented drug-delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bioabsorption with cannabinoids and nicotine by up to 10 times and, in some instances, with cannabinoids by as much as 27 times compared to standard industry formulations; reduce time of onset from one to two hours to minutes; and mask unwanted tastes; it is also being evaluated for orally administered antiviral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 25 patents granted and more than 50 patents pending worldwide. For more information about the company, please visit www.LexariaBioscience.com. 

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces $5M Registered Direct and Private Placement Offerings

InMed Pharmaceuticals (NASDAQ: INM) is a leader in the research, development, manufacturing and commercialization of rare cannabinoids. The company today announced its entry into securities purchase agreements with a single health care-focused institutional investor for the issuance and sale of 4,079,256 of its common shares, each at a purchase price of $0.858 (or pre-funded warrant in lieu thereof), in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, InMed has also agreed to issue and sell to the investor 1,748,250 common shares (or pre-funded warrant in lieu thereto) at the same purchase price as in the registered direct offering. In addition, the company has agreed to issue to the investor in the offerings unregistered preferred investment options to purchase up to an aggregate of 5,827,506 common shares. The company expects aggregate gross proceeds of approximately $5 million through both offerings, which are expected to close on or about June 6, 2022, subject to the satisfaction of customary conditions. InMed intends to use the net proceeds to continue pipeline development, advance commercial activities and for general working capital purposes. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offerings.

To view the full press release, visit https://cnw.fm/VSwXH

About InMed Pharmaceuticals Inc.

InMed Pharmaceuticals is a global leader in the research, development, manufacturing and commercialization of rare cannabinoids. Together with its subsidiary BayMedica LLC, the company has unparalleled cannabinoid manufacturing capabilities to serve a spectrum of consumer markets, including pharmaceutical and health and wellness. InMed is also a clinical-stage company developing a pipeline of rare cannabinoid therapeutics and dedicated to delivering new treatment alternatives to patients who may benefit from cannabinoid-based pharmaceutical drugs. For more information, visit www.InMedPharma.com and www.BayMedica.com.

NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://cnw.fm/INM

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — Study Says Cannabis Legalization Has Drastically Changed Marijuana Advertising

A recent study has concluded that the cannabis legalization wave sweeping across states and countries has triggered “drastic changes” in the way marijuana is advertised on Instagram. The research found that women are now more noticeable as “marijuana influencers,” and they drive cannabis marketing by posting about the way marijuana can be incorporated in one’s lifestyle.

This study is in stark contrast to pre-legalization years in which men where the more expected face of advertising illicit marijuana. The profiles of marijuana influencers now are also authentic, while those of the previous lot of marketers were anonymous or almost identifiable as fake because of the prohibition of marijuana in the target markets.

The study, whose findings were published in April, analyzed the profile pages of 60 apparently black-market sellers as well as 70 profile pages of cannabis influencers based within the United  States. The researchers focused a great deal on any notable text or visual differences.

The study findings indicate that Instagram is enabling marijuana influencers to flip the stereotypes about the illicit marijuana sector as being built around men. Today, cannabis is gaining the persona of a female user who wants the substance to meet a certain need in the female lifestyle. Such marketing is making it normal for women to use marijuana in the jurisdictions where it is legal.

The authors of the study note that such changes in the ways through which marijuana is marketed can influence consumption habits as well as shape the debate as people discuss the possibility of legalizing this plant.

The research team was also quick to observe that the current federal prohibition of marijuana had made it harder to market cannabis on social media platforms. This is because those platforms were actively censoring content in a bid to avoid being penalized by the federal government. This censorship takes place even in states where cannabis is legal.

It is now common to find cannabis influencers adding disclaimers to their posts, clarifying that the influencer isn’t in any way attempting to sell marijuana; instead, they note that they are only providing an explanation of the different ways in which they incorporate cannabis products in their lifestyles.

The study also notes that the female-dominated cannabis influencers in the United States largely focus their attention on how marijuana products can be used as lifestyle accessories while the previous generation of marketers tended to focus more on the marijuana itself, rather than its benefits. This shift in marketing now presents cannabis not as something hippie but as a substance that is compatible with motherhood, working out, and enjoying good health.

These evolving trends in cannabis marketing are likely to be followed closely by sector actors such as Flora Growth Corp. (NASDAQ: FLGC) in a bid to stay abreast of the latest trends that can help attain the objectives of the firms.

NOTE TO INVESTORS: The latest news and updates relating to Flora Growth Corp. (NASDAQ: FLGC) are available in the company’s newsroom at https://cnw.fm/FLGC

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — NIDA Seeks Additional Suppliers of Research-Grade Cannabis

The National Institute on Drug Abuse is seeking new partners that can supply cannabis for study purposes. Last week, the federal drug agency posted a notice on its website for organizations authorized by the DEA to grow marijuana that could acquire or produce marijuana and related materials for research.

Before the DEA recently ended the University of Mississippi’s monopoly on cannabis supply and agreed to approve new licenses, the National Institute on Drug Abuse had only a single supplier of marijuana for research. While the agency hasn’t stated how many suppliers it needs, it has listed the criteria for a prospective contract and the responsibilities the new partners would undertake.

In the notice, the agency stated that interested parties would need to be able to procure or produce marijuana, marijuana extract and other marijuana-derived materials for clinical and basic research. In addition, the parties would be required to carry out stability determination, qualitative and quantitative analysis, and recommend suitable conditions for the storage of these products for approved studies.

The agency also revealed that it hoped its studies would focus on less-known cannabinoids such as CBG, CBC and CBN, in addition to better-known ones, including CBD and THC. The agency then noted that organizations that were interested needed to document and demonstrate that they had considerable experience and were capable of administering and coordinating interrelated tasks in a timely and effective manner.

For some time, legislators and experts have been protesting against the exclusive supply of cannabis that the National Institute on Drug Abuse had depended on, arguing that research done using this cannabis had skewed findings. Researchers added that the marijuana’s status under the Controlled Substances Act also hindered studies on marijuana. The status discourages scientists from taking on research on marijuana, as has been stated by Nora Volkow, head of the National Institute on Drug Abuse.

In a recent interview, Volkow revealed that she herself wasn’t keen on going through the taxing process of acquiring approval to conduct research on substances such as cannabis because they were classified under Schedule I. Many hope that once the DEA approves more cannabis manufacturers, the quality and diversity of marijuana products will increase, even if the substance remains classified under Schedule I.

In addition to giving approval to new manufacturers, the Drug Enforcement Administration is planning to increase yearly production quotas for cannabis and psilocybin, among other substances, as demand from the scientific community continues to grow.

As the conditions that companies such as Cannabis Strategic Ventures Inc. (OTC: NUGS) have to meet in order to study marijuana ease, we are likely to see plenty of data-backed information becoming available to the public and policymakers.

NOTE TO INVESTORS: The latest news and updates relating to Cannabis Strategic Ventures Inc. (OTC: NUGS) are available in the company’s newsroom at http://cnw.fm/NUGS

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.